On June 27, 2014, the FDA approved Afrezza, an inhaled insulin for mealtime use, bringing this form of therapy back to the market after a 7-year absence.1 The approval covers patients with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, and follows an extensive review process, one that required the drug’s manufacturer, the MannKind Corporation, to perform additional clinical trials at FDA’s behest 3 years ago.2
Inhaled insulin got its first try in 2006, when Pfizer brought Exubera to the market. But the oversized inhaler was cumbersome and unpopular with patients and physicians alike. The product failed miserably and was pulled a year later.
By contrast, Afrezza’s small inhaler fits in the palm of a hand, and T1DM advocates who spoke with Evidence-Based Diabetes Management in May said it appeared MannKind had done its homework with patients this time around.3
“(This) approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels,” Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the Center for Drug Evaluation and Research, said in a statement released by FDA.1
Afrezza is not for every person who requires insulin. FDA’s approval comes with a boxed warning, the strongest type, that the product should not be used by smokers or persons with chronic obstructive pulmonary disorder.1 Nor is Afrezza a substitute for long-acting insulin; rather, it is a mealtime complement for that product for T1DM patients; those with T2DM can use Afreeza with oral therapy. The inhaled product is seen as a means to get T2DM patients who need insulin to use it when they might otherwise avoid it, due to fear of needles.
According to the FDA, the approval includes requirements for 4 postmarketing studies for Afrezza: a clinical trial to evaluate pharmacokinetics, safety, and efficacy in pediatric patients; a clinical trial to evaluate long-term risks of lung cancer and cardiovascular function; and 2 studies to evaluate dose-response and within-subject variability.1References
1. FDA approves Afrezza to treat diabetes [press release]. Silver Spring, MD: FDA; June 27, 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403122.htm.
2. Wilemon T. FDA approves inhaled form of insulin. USA Today. http://www.usatoday.com/story/news/nation/2014/06/28/fda-inhaled-insulindiabetes-afrezza/11612739/. Published June 28, 2014. Accessed June 30, 2014.
3. Mehr S. Inhaled insulin’s long journey to commercialization. Am J Manag Care. 2014;20(SP8):SP253-SP254.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
Therapists’ Perspectives on Access to Telemental Health Among Medicaid-Enrolled Youth
November 10th 2023This qualitative study elucidates therapists’ perspectives on barriers to and facilitators of access to telemental health among Medicaid-enrolled youth served by a large safety-net organization.
Read More
Incidence and Cost of Potentially Avoidable Emergency Department Visits for Urolithiasis
November 10th 2023This study characterizes the incidence and associated factors of urolithiasis-related emergency department visits that are potentially preventable with appropriate ambulatory care and calculates their cumulative costs.
Read More